Patents by Inventor Robert T. Yu

Robert T. Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9
    Publication number: 20240245677
    Abstract: Selected BRD9 protein degradation compounds and morphic forms thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.
    Type: Application
    Filed: March 8, 2024
    Publication date: July 25, 2024
    Applicant: C4 THERAPEUTICS, INC.
    Inventors: Katrina L. Jackson, Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap, Minsheng He, Robert T. Yu, Matthew J. Schnaderbeck, Kathleen Neville, Siyi Jiang, Meiqi Li, Qianwei Liu, Manjie Zheng, Jia Li, Liwei Zhang
  • THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF
    Publication number: 20240199581
    Abstract: The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.
    Type: Application
    Filed: December 8, 2023
    Publication date: June 20, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveshuk, Katrina L. Jackson, Yanke Liang, Robert T. Yu, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Morgan Welzel O'Shea, Gesine Kerstin Veits, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Daniela Krummenacher, Piergiorgio Franceso Tommaso Pettazzoni, Juergen Wichmann
  • COMPOUNDS FOR TARGETED DEGRADATION OF RET
    Publication number: 20230233692
    Abstract: Novel compounds which act as protein degradation inducing moieties for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET.
    Type: Application
    Filed: February 3, 2023
    Publication date: July 27, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: James A. Henderson, Christopher G. Naveschuk, Kiel Lazarski, Victoria Garza, Moses Moustakim, Jae Young Ahn, Gesine Kerstin Veits, Morgan Welzel O'Shea, Ryan E. Michael, Jeremy L. Yap, Yanke Liang, Andrew Charles Good, Mark E. Fitzgerald, Robert T. Yu
  • BRAF DEGRADERS
    Publication number: 20230145336
    Abstract: Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: December 19, 2022
    Publication date: May 11, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Mark E. Fitzgerald, Victoria Garza, Andrew Charles Good, Katrina L. Jackson, Yanke Liang, Moses Moustakim, Morgan Welzel O'Shea, Gesine Kerstin Veits, Jeremy L. Yap, Robert T. Yu, Cosimo Dolente, David Stephen Hewings, Daniel Hunziker, Bernd Kuhn, Piergiorgio Francesco Tommaso Pettazzoni, Fabienne Ricklin, Claus Riemer, Juergen Wichmann
  • CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS
    Publication number: 20210171555
    Abstract: We provide diastereomerically pure or substantially diastereomerically pure activated phosphoramidochloridate morpholino nucleosides, methods of their preparation, and methods of their use in stereospecific coupling for stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs).
    Type: Application
    Filed: October 28, 2020
    Publication date: June 10, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi ENDO, Robert T. YU, Francis FANG, Hyeong Wook CHOI, Mingde SHAN
  • Substituted phosphorodiamidate morpholino oligomers
    Patent number: 10836784
    Abstract: A phosphoramidochloridate morpholino monomer of the following formula is provided:
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: November 17, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Atsushi Endo, Robert T. Yu, Francis Fang, Hyeong Wook Choi, Mingde Shan
  • CHIRAL REAGENTS FOR PREPARATION OF SUBSTITUTED PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS
    Publication number: 20200115405
    Abstract: A method of preparation of stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs) of one of the following general formulas is provided.
    Type: Application
    Filed: September 17, 2019
    Publication date: April 16, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi ENDO, Robert T. YU, Francis FANG, Hyeong Wook CHOI, Mingde SHAN
  • Chiral reagents for preparation of substituted phosphorodiamidate morpholino oligomers
    Patent number: 10457698
    Abstract: A method of preparation of stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs) of one of the following general formulas is provided:
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: October 29, 2019
    Assignee: Eisai R&D Management Co., Ltd
    Inventors: Atsushi Endo, Robert T. Yu, Francis Fang, Hyeong Wook Choi, Mingde Shan
  • CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS
    Publication number: 20180222932
    Abstract: We provide diastereomerically pure or substantially diastereomerically pure activated phosphoramidochloridate morpholino nucleosides, methods of their preparation, and methods of their use in stereospecific coupling for stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs).
    Type: Application
    Filed: August 5, 2016
    Publication date: August 9, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi Endo, Robert T. Yu, Francis Fang, Hyeong Wook Choi, Mingde Shan
  • Selectively substituted quinoline compounds
    Patent number: 9663486
    Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: May 30, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Roch Boivin, Hans Hansen, Sally Ishizaka, Matthew Mackey, Shawn Schiller, Chikako Ogawa, Sridhar Narayan, Peter Bertinato, Gregory Berger, Atsushi Endo, Robert T. Yu, Lynn Hawkins
  • Trioxacarcins and uses thereof
    Patent number: 9611287
    Abstract: The present invention relates to trioxacarcin compounds of the formula: or pharmaceutically acceptable forms thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined herein. The present invention also provides processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; and methods of use and treatment.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: April 4, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Nicholas E. Hill, Jakub Svenda, Robert T. Yu, Daniel J. Smaltz, Thomas Magauer
  • TRIOXACARCINS AND USES THEREOF
    Publication number: 20160355537
    Abstract: The present invention relates to trioxacarcin compounds of the formula: or pharmaceutically acceptable forms thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined herein. The present invention also provides processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; and methods of use and treatment.
    Type: Application
    Filed: July 28, 2015
    Publication date: December 8, 2016
    Applicant: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Nicholas E. Hill, Jakub Svenda, Robert T. Yu, Daniel J. Smaltz, Thomas Magauer
  • SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS
    Publication number: 20160176841
    Abstract: Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Application
    Filed: October 14, 2014
    Publication date: June 23, 2016
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Roch BOIVIN, Hans HANSEN, Sally ISHIZAKA, Matthew MACKEY, Shawn SCHILLER, Chikako OGAWA, Sridhar NARAYAN, Peter BERTINATO, Gregory BERGER, Atsushi ENDO, Robert T. YU, Lynn HAWKINS
  • Trioxacarcins and uses thereof
    Patent number: 9102697
    Abstract: The present invention relates to trioxacarcin compounds of the formula: (I) or pharmaceutically acceptable forms thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined herein. The present invention also provides processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; and methods of use and treatment.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: August 11, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Nicholas E. Hill, Jakub Svenda, Robert T. Yu, Daniel J. Smaltz, Thomas Magauer
  • TRIOXACARCINS AND USES THEREOF
    Publication number: 20130150314
    Abstract: The present invention relates to trioxacarcin compounds of the formula: (I) or pharmaceutically acceptable forms thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined herein. The present invention also provides processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; and methods of use and treatment.
    Type: Application
    Filed: March 22, 2011
    Publication date: June 13, 2013
    Applicant: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Nicholas E. Hill, Jakub Svenda, Robert T. Yu, Daniel J. Smaltz, Thomas Magauer